Policy:
Evaluating and publicly designating regulatory authorities as WHO listed authorities

Please send any comments you may have to Mr Mohamed Refaat, Technical Officer, Regulatory Systems Strengthening, Regulation and Safety Unit (refaatm@who.int), with a copy to Yvonne Melounou (melounouy@who.int) by 15 September 2020. Please use our attached Comments Table for this purpose.

Our working documents are sent out electronically and they will also be placed on the WHO Medicines website (http://www.who.int/medicines/areas/quality_safety/quality_assurance/guidelines/en/) for comments under the “Current projects” link. If you wish to receive all our draft guidelines, please send your email address to jonessi@who.int and your name will be added to our electronic mailing list.

© World Health Organization 2020
All rights reserved.
SCHEDULE FOR THE PROPOSED USE OF DOCUMENT QAS/19.828/Rev.1:

**Policy:**
Evaluating and publicly designating regulatory authorities as WHO listed authorities

<table>
<thead>
<tr>
<th>Description of activity</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendation by the Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP) to develop a definition and approach to replace “Stringent Regulatory Authorities” based on WHO benchmarking of regulatory systems.</td>
<td>October 2017</td>
</tr>
<tr>
<td>Preparation of a concept note on a <em>Framework for evaluating and publicly designating regulatory authorities as WHO Listed Authorities.</em></td>
<td>April 2019</td>
</tr>
<tr>
<td>Web posting of concept note for a comment period of eight (8) weeks.</td>
<td>17 May 2019</td>
</tr>
<tr>
<td>Preparation of first draft of WHO Listed Authorities (WLA) policy document based on the outcome of a public consultation on the WLA concept note.</td>
<td>September 2019</td>
</tr>
<tr>
<td>Discussion of first draft at a consultative meeting with Member States and a stakeholder meeting.</td>
<td>September 2019</td>
</tr>
<tr>
<td>Revision of first draft of the WLA policy document based on feedback received at the meetings.</td>
<td>October–December 2019</td>
</tr>
<tr>
<td>Web posting of second draft WLA policy document with draft WLA definition for a comment period of eight (8) weeks.</td>
<td>20 December 2019</td>
</tr>
<tr>
<td>Preparation of consolidated third draft based on the outcomes of the public consultation.</td>
<td>March–June 2020</td>
</tr>
<tr>
<td>Convening consultative meetings of Member States and stakeholders to discuss the updated WLA policy document with WLA definition.</td>
<td>June/July 2020</td>
</tr>
<tr>
<td>Preparation of a fourth draft WLA policy document based on the outcome of a consultation with Member States and stakeholders.</td>
<td>July 2020</td>
</tr>
<tr>
<td>Web posting and circulation for public consultation of fourth draft WLA policy document with draft WLA definition for a comment period of six (6) weeks.</td>
<td>August – mid-September 2020</td>
</tr>
<tr>
<td>Consolidation of comments and revision of the draft policy resulting in a fifth draft and follow up action, as needed.</td>
<td>September 2020</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Discussion/adoption of the WLA definition as an element of the fifth draft of the WLA policy document at the meetings of the ECSPP and the Expert Committee on Biological Standardization.</td>
<td>October 2020</td>
</tr>
<tr>
<td>Finalisation and approval of WLA policy document, translation and publication.</td>
<td>31 December 2020</td>
</tr>
</tbody>
</table>
Policy:
Evaluating and publicly designating regulatory authorities as WHO listed authorities

Contents
1. Introduction
2. Context
3. Purpose
4. Scope
5. Policy statement
6. Definition
7. Operating principles
8. Glossary

References
1. Introduction

This policy on the evaluation and designation of regulatory authorities as WHO Listed Authorities (WLA) was developed following broad public consultation and the review of written comments received from the publication of a concept note (1), which informed the drafting of a first version of the WLA policy and operational guidance, as well as international consultative meetings with Member States and interested stakeholders (2, 3). It also considers recommendations from the fifty-second meeting of the World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP) on the replacement of the term “stringent regulatory authority” with “WHO-listed Authority” (4). The ECSPP recommendations were based on comments received on the proposed elements of a replacement definition for Stringent Regulatory Authorities (SRAs) posted by WHO for public comment in August 2017 that was intended to provide a more transparent, robust and equitable measure of regulatory performance (5).

2. Context

World Health Assembly Resolution 67.20 (WHA 67.20) on Regulatory system strengthening for medical products (6) recognizes that effective regulatory systems are an essential component of health system strengthening, necessary for the implementation of universal health coverage and, ultimately, contribute to better public health outcomes. Resolution WHA 67.20 also recognizes that inefficient regulatory systems can be a barrier to access to safe, effective and quality medical products. Several WHO regional committee resolutions on regulatory system strengthening have also been adopted, including, for example, Regional Committee Resolution (CD50.R9), 2010, in the WHO Regional Office for the Americas (AMRO/PAHO) (7), Regional strategy for improving access to essential medicines in the Western Pacific Region (2005-2010) (8), and document AF/RC63/7 of the WHO Regional Office for Africa (AFRO) (9). The road map for access to medicines, vaccines and other health products highlights regulatory system strengthening as an integral part of a health systems approach to improving access to safe and effective medical products of assured quality (10).

Resolution WHA 67.20 calls upon WHO to:

a) apply evaluation tools to generate and analyse evidence of regulatory system performance;
b) facilitate the formulation and implementation of institutional development plans; and
c) provide technical support to national regulatory authorities and governments.
The WHO supports Member States in strengthening regulatory systems as a means of promoting equitable access to and availability of quality assured medical products. To assist countries in reaching and sustaining a level of medical product regulatory oversight that is effective, efficient and transparent, WHO has implemented a regulatory system strengthening programme. Its objectives are to:

- promote regulatory cooperation, convergence and transparency through networking, work-sharing and reliance; and
- build regulatory capacity in Member States consistent with good regulatory practices.

In order to reach these objectives, WHO has established the framework, principles, tools and processes to, among others, a) evaluate regulatory systems and establish maturity levels by applying the Global Benchmarking Tool (GBT) (11) and b) evaluate regulatory performance in order to designate authorities responsible for regulation of medical products as WLA.

### 3. Purpose

The principle of reliance is central to WHO’s approach to regulatory system strengthening and effective regulation, regardless of the size and maturity of the authority (12). Regulatory cooperation and reliance are built on trust and confidence which, in turn, depend on greater knowledge and transparency of the regulatory systems and the performance of the regulatory authority upon which others may rely.

The introduction of a framework for designating and publicly listing a regulatory authority as a WLA provides a transparent and evidence-based pathway for regulatory authorities to be globally recognized as meeting and applying WHO and other internationally recognized standards and guidelines, as well as good regulatory practices. The main purpose of the introduction of the WLA designation is the replacement of the concept of an SRA which was initially developed to guide global procurement of medicines. This concept has been used by the WHO Secretariat and the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to guide medicine procurement decisions and has subsequently become widely recognized by the international regulatory and procurement community. The definition of an SRA, first published by the Global Fund in 2008, was based on membership in the International Conference (now Council) of Harmonization (ICH) (13) but the utilization of this concept has been documented since 2003. An interim definition adopted by ECSPP in 2017 restricted eligibility to ICH
membership prior to 23 October 2015 while awaiting the development of a more suitable definition and approach based on the WHO benchmarking of regulatory systems (14).

The WLA framework is also replacing the concept and procedure for recognizing regulatory authorities exhibiting ‘a high level of performance’ in vaccine regulation based on criteria defined in the WHO Technical Report Series (TRS) 978 (15).

The GBT is and remains the foundation for assessing the regulatory systems based on inputs, processes and outputs. Based on this, the WLA framework is meant to provide a more detailed picture of how a regulatory system operates through an additional performance evaluation process that examines key regulatory outputs and consistency in adherence to international standards and guidelines as well as good regulatory practices.

It should be noted that in 2019, an estimated 75% of the 194 Member States were estimated to not have a stable and well-functioning regulatory system corresponding to maturity level (ML) 3 or 4, with ML 3 being the target of Resolution WHA 67.20. Bringing these regulatory systems to ML 3 will require significant and sustained efforts and a ‘smart’ regulatory approach based on reliance on other mature and trusted reference regulatory authorities—the WLAs—whenever possible.

The designation of a regulatory authority as a WLA is ultimately meant to promote access and the supply of safe, effective and quality medical products by facilitating the use of reliance on the work products and decisions of trusted agencies in the regulatory decision-making of regulatory authorities and the procurement decisions of the United Nations (UN) and other agencies to reduce the redundancy and waste of limited regulatory and financial resources.

4. Scope

This policy describes the purpose, definitions and operating principles related to the evaluation and public listing of authorities responsible for the regulation of medical products as WHO Listed Authorities or WLAs. The initial scope of the WLA designation will be limited to medicines and vaccines, with an option to expand to other categories of products in the future in line with the expansion of the scope of the GBT.
5. **Policy statement**

Independent, efficient, science-based and transparent regulatory systems are essential to health care systems, access to safe, effective and quality medical products and the implementation of universal health coverage. A system for publicly designating regulatory authorities as WLAs provides an evidence-based mechanism to evaluate, recognize and transparently classify and list well-performing regulatory systems. It thereby, where appropriate, intends to:

a) promote trust, confidence and reliance between regulatory authorities;

b) encourage continuous improvement of regulatory systems and the efficient use of regulatory resources;

c) expand the pool of regulatory authorities beyond SRAs for users such as regulatory authorities or the WHO Prequalification (PQ) Programme;

d) promote the supply of safe, effective and quality assured medical products for use by UN procurement agencies and countries; and

e) create an enabling environment for innovation and local production of medical products by facilitating the implementation of reliance approaches and therefore accelerating access to safe, effective and quality assured medical products.

6. **Definition of a WHO Listed Authority**

A WHO Listed Authority (WLA) is a regulatory authority\(^1\) or a regional regulatory system which has been documented to comply with all the indicators and requirements specified by WHO for listing based on an established benchmarking and performance evaluation process.

7. **Operating principles**

The following principles define in broad terms how the WLA framework is to be implemented. Details are provided in the *WLA Operational Guidance* and accompanying procedures.

\(^1\) A regulatory authority is meant to cover all the institutions, working together in an integrated and effective manner, that are responsible for the regulatory oversight of medical products in a given country or region.
a) The process to establish a WLA is initiated by a request from the Member State; for a regional regulatory system (RRS), the request should come from a regional body, where it exists, or another institution representing the RRS, following coordination with the individual authorities that are part of the system, as appropriate.

b) The GBT forms the basis for evaluating the ML. The WLA performance evaluation process assesses the consistent performance including adherence to international standards and guidelines, as well as good regulatory practices of the regulatory authority or RRS over time against the requirements established for the scope of listing being sought.

c) A regulatory authority or RRS can be listed for one or more product categories and/or for one or more regulatory functions.

d) Regulatory authorities or RRSs must at least have attained overall ML 3 as established by the GBT to be eligible for consideration as a WLA.

e) A WLA is expected to have the capacity and established track record of performing the regulatory functions for the product categories relevant to the scope of the WLA listing. A WLA can rely in a targeted way based on a defined approach on others for these functions and/or products categories, but full reliance cannot be used as a substitute for reliable performance of regulatory functions/for product categories which are assessed as part of the listing.

f) After the WHO confirms eligibility criteria are met, the regulatory authority or the RRS and WHO agree to a written plan of performance evaluation and commit the necessary resources to execute the plan, which may be adjusted from time to time. The plan agreed, the resources involved and the time for execution of the plan will depend on the requested scope, the completeness of the documentation as well as the readiness of the regulatory authority or RRS.

g) In considering the extent and depth of the evaluation process, factors such as existing evidence and track record of regulatory function and performance, including from previous benchmarking/audit exercises undertaken by WHO or other organizations such as, for example, the Pharmaceutical Inspection Co-operation Scheme (PIC/S), Benchmarking of European Medicines Agencies (BEMA) or the International Organization for Standardization (ISO) of the regulatory authority or RRS, should be taken into consideration when determining compliance with the requirements for designation as a WLA in order to make best use of limited resources for performance evaluation and avoid unnecessary burden and ensure optimal use of resources.

h) The degree of integration on the basis of a common framework varies between different regional regulatory systems which should also be taken into account in the designation of these systems.

i) All non-public information provided is kept confidential.
Following the successful completion of the WLA evaluation process, a regulatory authority or RRS is publicly listed as a WLA in the list of reference authorities (16). The listing as a WLA includes the scope of the designation (product categories and/or regulatory functions); evidence reviewed, and the process undertaken to support the listing; the original date and the period of validity of the initial listing.

A listing will initially be valid for a period of 5 years unless extended. A risk-based process will be used to renew the initial listing. Once renewed, the listing will no longer be subject to a validity period but to a continuous monitoring based on risk management principles to ensure that requirements for the listing continue to be met.

Changes or events that could cause sufficient concern that the requirements for the listing are no longer met will trigger a re-evaluation of the WLA. The re-evaluation will be risk-based and will focus on the issues of concern.

To ensure impartiality of the WLA process, a recommendation to list or delist a regulatory authority or RRS is made following a review of the evaluation report on the candidate WLA by an advisory committee. This committee will be set up by WHO based on established and transparent criteria such as ensuring equitable geographical representation, gender balance and professional competencies in order to provide a representation of different approaches and practical experience from all regions of the world. The review process provides an additional level of assurance that due process was followed and that decisions are supported by findings.

WHO reserves the right to delist a WLA should, upon evaluation and subsequent discussion with the regulatory authority or RRS, it be concluded that the basis for supporting the listing is no longer valid. Delisting and the rationale for delisting are published on the WHO website. The decision to delist would follow a meeting with the regulatory authority or the RRS during which the authority would have an opportunity to present its case.

The ultimate responsibility and decision for use of the list resides with the users (e.g. regulatory authorities, WHO Prequalification Programme, procurement agencies) and depends on the specific context of its intended use.

The designation of WLAs is meant to substantiate the maturity level using an international benchmark, as defined by the GBT and the performance of regulatory authorities and RRSs using the WLA performance evaluation process. It is not meant to make any inference regarding the maturity or performance of a regulatory authority or RRS that has been evaluated by other institutions or through other procedures.
8. Glossary

Common regulatory framework. A common regulatory framework is a unified set of requirements, processes and controls applied in the supervision of medical products. For a common legal framework this is, in addition, underpinned by common legislation.

International standards and guidelines. For the purpose of this document, the term includes relevant WHO standards and guidelines and any other relevant internationally recognized standards (e.g. ISO or pharmacopoeial standards) and guidelines (e.g. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) or PIC/S guidelines).

Maturity level (ML). The maturity of regulatory systems is divided into four levels, characterized as follows:

- **ML1**: some elements of regulatory systems exist;
- **ML2**: evolving national regulatory systems that partially perform essential regulatory functions;
- **ML3**: stable, well-functioning and integrated regulatory systems; and
- **ML4**: regulatory systems operating at advanced level of performance and continuous improvement.

Product category(ies). Refers to “medical products” which may include the following product categories: vaccines, medicines, medical devices including in-vitro diagnostics, blood and blood products and vector control products.

Regional regulatory system (RRS). A system composed of individual regulatory authorities, or a regional body composed of individual regulatory authorities, operating under a common regulatory framework including or excluding a common legal framework. The common framework must at least ensure equivalence between the members in terms of regulatory requirements, practices and quality assurance policies. The system or regional body, where it exists, may have enforcement powers to ensure compliance with the common regulatory framework. A RRS so described may be considered a single entity and therefore eligible for listing as a WLA, as well as each of the individual authorities that are part of the system. In cases where a RRS is further underpinned by a common legal framework, it should be considered as a single entity and, as such, eligible for listing as a WLA, as well as each of the individual authorities that are part of the system.
Regulatory function(s). The term refers to the regulatory functions as components of a regulatory system for medical products defined in the GBT being national regulatory systems, registration and marketing authorization, vigilance, market surveillance and control, licensing establishments, regulatory inspection, laboratory testing, clinical trials oversight, and national regulatory authorities (NRA) lot release.

Reliance. The act whereby the (national) regulatory authority in one jurisdiction may take into account and give significant weight to assessments performed by another (national) regulatory authority or trusted institution, or to any other authoritative information in reaching its own decision. The relying authority remains independent, responsible and accountable for decisions taken, even when it relies on the decisions and information of others.

Stringent regulatory authority (interim definition ECSPP). A regulatory authority which is:

a) a member of the ICH, being the European Commission, the United States (U.S.) Food and Drug Administration and the Ministry of Health, Labour and Welfare of Japan, also represented by the Pharmaceuticals and Medical Devices Agency (as before 23 October 2015); or

b) an ICH observer, being the European Free Trade Association, as represented by Swissmedic, and Health Canada (as before 23 October 2015); or

c) a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement, including Australia, Iceland, Liechtenstein and Norway (as before 23 October 2015) [6].
References


12. WHO Good Reliance Practices (GReP) (link to document to be added after start of public consultation).


Technical Report Series, No. 978;

https://www.who.int/biologicals/expert_committee/TRS_978_61st_report.pdf?ua=1,

accessed 31 July 2020.

16. “List of reference authorities”


***